Therapeutic Expertise
At MDL Clintech Limited, our clinical pharmacology, bioanalytical, and regulatory capabilities span key therapeutic areas central to global healthcare and generic drug development. We combine robust BE/BA study execution with advanced in vitro biowaiver strategies, delivering high-precision pharmacokinetic (PK) data and regulatory documentation tailored to the unique physiological and chemical challenges of each therapeutic class.
Oncology & Haematology
Evaluating oral oncology agents requires navigating narrow therapeutic windows, high pharmacokinetic variability, and stringent safety controls. MDL Clintech provides specialized BA/BE study designs in healthy volunteer cohorts or patient-based populations when ethically indicated. Our bioanalytical laboratories employ high-sensitivity LC-MS/MS platforms to quantify ultra-trace drug and active metabolite concentrations, while our regulatory team prepares robust justification packages and safety protocols compliant with global oncology guidance
Dermatology
Topical and dermatological formulations require specialized bioequivalence approaches to demonstrate local availability and systemic safety. We conduct standard BA/BE evaluations and leverage biowaiver pathways for line extensions and proportional strengths, ensuring seamless market entry for creams, gels, ointments, and oral therapies
Neuroscience & CNS
Central Nervous System (CNS) therapeutics, including antiepileptics, antidepressants, antipsychotics, and analgesics, often present complex absorption kinetics, significant first-pass metabolism, and central side-effect profiles. MDL Clintech manages both immediate- and modified-release CNS BA/BE studies with rigorous subject safety monitoring, standardized confinement conditions, and precise blood-sampling schedules to accurately characterize Cmax, Tmax, and elimination half-lives
Biosimilar Development (Clinical PK/PD Support)
For biosimilar and follow on biologic programs, demonstrating pharmacokinetic (PK) and pharmacodynamics (PD) equivalence against the reference product is the cornerstone of early development. MDL Clintech provides specialized clinical pharmacology unit support for single- and multiple-dose comparative PK/PD bridging studies in healthy volunteers. Our scientific team ensures precise bioanalytical sample handling, cold-chain integrity, and statistical bioequivalence assessment aligned with WHO, EMA, and US FDA biosimilar development guidelines
Infectious Disease
From high-burden global health priorities, such as broad-spectrum antibiotics and novel antivirals, infectious disease therapeutics represent a core pillar of our expertise. We execute complex crossover and steady-state BA/BE trials evaluating food-effect interactions and fixed-dose combinations (FDCs). In parallel, we provide comprehensive BCS-based biowaiver evaluations (Class I and III), supporting WHO Prequalification dossiers and regional African registrations to accelerate access to essential anti-infectives
Pulmonology
Inhalation and respiratory therapies require a distinct combination of in vitro characterization and clinical pharmacokinetics to establish therapeutic equivalence. MDL Clintech supports systemic oral pulmonary treatments (such as bronchodilators, leukotriene receptor antagonists, and modified-release xanthines). We conduct systemic bioavailability trials to ensure complete regulatory readiness across regional and international jurisdictions
